Point72 Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Point72 Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$46.9M	Buy	5,534,985 +4,518,737	+445%	+$43.1M	0.06%	403
2025 Q4	$12.3M	Sell	1,016,248 -3,585,073	-78%	-$43.5M	0.01%	1229
2025 Q3	$53.8M	Buy	4,601,321 +2,697,107	+142%	+$32.3M	0.09%	254
2025 Q2	$17.7M	Sell	1,904,214 -38,148	-2%	-$299K	0.03%	542
2025 Q1	$14.2M	Sell	1,942,362 -993,562	-34%	-$7.64M	0.03%	549
2024 Q4	$25.1M	Buy	2,935,924 +895,304	+44%	+$8.73M	0.06%	385
2024 Q3	$17.8M	Sell	2,040,620 -666,043	-25%	-$5.49M	0.05%	453
2024 Q2	$18.5M	Buy	+2,706,663	New	+$16.7M	0.05%	418
2022 Q4	–	Sell	-1,000	Closed	-$4K	–	1713
2022 Q3	$4K	Sell	1,000 -49,000	-98%	-$247K	﹤0.01%	1353
2022 Q2	$201K	Buy	+50,000	New	+$189K	﹤0.01%	1284

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's OCUL Position: Q1 2026 in Review

Point72 Asset Management increased its Ocular Therapeutix (OCUL) stake by 445% in Q1 2026, buying an estimated $43.1M and bringing the position to 5,534,985 shares worth $46.9M. The position accounts for 0.06% of the portfolio, ranked #403.

Point72 Asset Management first reported a position in OCUL in Q2 2022 and has held it in 10 quarters since. The position peaked at $53.8M in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Point72 Asset Management held 5,534,985 shares of Ocular Therapeutix worth $46.9M as of Q1 2026.
Point72 Asset Management bought 4,518,737 Ocular Therapeutix shares in Q1 2026, an estimated $43.1M.
Ocular Therapeutix made up 0.06% of Point72 Asset Management's portfolio in Q1 2026, its #403 holding.
Point72 Asset Management first reported a position in Ocular Therapeutix in Q2 2022 and has held it in 10 quarters since.
Point72 Asset Management's Ocular Therapeutix position peaked at $53.8M in Q3 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.